Compare NMG & PRTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NMG | PRTA |
|---|---|---|
| Founded | 2011 | 2012 |
| Country | Canada | Ireland |
| Employees | N/A | N/A |
| Industry | Other Metals and Minerals | Biotechnology: Pharmaceutical Preparations |
| Sector | Basic Materials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 671.4M | 539.9M |
| IPO Year | 2015 | 2013 |
| Metric | NMG | PRTA |
|---|---|---|
| Price | $1.91 | $9.77 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 2 | 9 |
| Target Price | $5.75 | ★ $19.00 |
| AVG Volume (30 Days) | ★ 946.2K | 399.3K |
| Earning Date | 05-13-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ 0.60 |
| Revenue | N/A | ★ $814,000.00 |
| Revenue This Year | N/A | $1,111.38 |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $16.32 |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.60 | $4.32 |
| 52 Week High | $6.06 | $11.80 |
| Indicator | NMG | PRTA |
|---|---|---|
| Relative Strength Index (RSI) | 40.72 | 42.33 |
| Support Level | $1.81 | $9.66 |
| Resistance Level | $2.00 | $10.11 |
| Average True Range (ATR) | 0.11 | 0.61 |
| MACD | -0.02 | -0.19 |
| Stochastic Oscillator | 25.56 | 17.46 |
Nouveau Monde Graphite Inc is a mineral exploration company. The company specializes in the exploration, evaluation, and development of mineral properties located in Quebec and is developing a natural graphite-based anode material that would qualify as battery-grade material to supply the lithium-ion industry. The Company currently operates in two segments: the Mining projects (which includes the Matawinie Mine project and the Uatnan Mining Project) and the Battery Material Plant project.
Prothena Corp PLC is a late-stage clinical biotechnology company that focuses on protein dysregulation and a pipeline of investigational therapeutics with the potential to change the course of devastating neurodegenerative and rare and peripheral amyloid diseases. Prothena is developing and applying its proprietary CYTOPE technology to target a broad spectrum of intracellular disease pathways in the brain and periphery. The company's pipeline includes both wholly-owned and partnered programs like Prasinezumab, Coramitug (PRX004), BMS-986446 (PRX005), PRX019, TDP-43 CYTOPE, and PRX012-TfR, being developed for the potential treatment of Parkinson's disease, ATTR amyloidosis with cardiomyopathy, Alzheimer's disease, Amyotrophic lateral sclerosis (ALS), and other neurodegenerative diseases.